Effect of ramiprilat or captopril on myocardial infarct size: Assessment in canine models of ischemia alone and ischemia with reperfusion

Pharmacology

Volumn 57, Issue 1, 1998, Pages 35-46

  Black, Shawn C ^a,b   Driscoll, Edward M ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Angiotensin converting enzyme; Angiotensin converting enzyme inhibitor; Captopril; Myocardial ischemia; Ramiprilat; Reperfusion injury

Indexed keywords

CAPTOPRIL; RAMIPRILAT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG INFUSION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CAPTOPRIL; CORONARY CIRCULATION; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DOGS; EVALUATION STUDIES; HEART RATE; HEMODYNAMIC PROCESSES; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; RAMIPRIL;

EID: 0031809154     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028224     Document Type: Article

References (22)

1. Ertl G, Kloner RA, Alexander RW, Braunwald E: Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982;65:40-48.
2. Hock CE, Ribeiro LGT, Lefer AM: Preservation of ischemie myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction. Am Heart J 1985;109:222-228.
3. Li K, Chen X: Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat. J Mol Cell Cardiol 1987; 19:909-915.
4. Mehta PM, Alker KJ, Kloner RA: Functional infarct expansion, left ventricular dilation and isovolumic relaxation time after coronary occlusion: A two-dimensional echocardiographic study. J Am Coll Cardiol 1988;11:603-606.
5. Liang C-S, Gavras H, Black J, Sherman LG, Hood WB: Renin-angiotensin system inhibiton in acute myocardial infarction in dogs. Circulation 1982;66:1249-1254.
6. Daniell HB, Carson RR, Ballard KD, Thomas GR, Privitera PJ: Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol 1984;6:1043-1047.
7. de Lorgeril M, Ovize M, Delaye J, Renaud S: Importance of flow perfusion deficit in the response to captopril in experimental myocardial infarction. J Cardiovasc Pharmacol 1992;19:324-329.
8. Becker RHA, Scholkens BA: Ramipril: Review of pharmacology. Am J Cardiol 1987;59:3-11.
9. Linz W, Scholkens B, Han YF: Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol 1986;8(suppl 10):91-99.
10. Martorana PA, Kettenbach B, Breipohl G, Linz W, Scholkens BA: Reduction of infarct size by local angiotensin converting enzyme inhibitor is abolished by a bradykinin antagonist. Eur J Pharmacol 1990;182: 395-396.
11. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ: Reduction of myocardial infarct size in rabbits by ramiprilat: Reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993;21:996-1003.
12. Grover GJ, Sleph PG, Dzwonczyk S, et al: Effects of different angiotensin-converting enzyme (ACE) inhib-itors on ischemic isolated rat hearts. Relationship between cardiac ACE inhibitor and cardioprotection. J Pharmacol Exp Ther 1991;102:769-773.
13. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson D, Taylor AA, Smith CW: Inflammation in the course of early myocardial ischemia. FASEB J 1991;5:2529-2537.
14. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR: Reduction of the extent of myocardial injury by neutrophil depletion in the dog. Circulation 1983;67: 1016-1023.
15. Jugdutt BI: Myocardial salvage by intravenous nitroglycerin in conscious dogs: Loss of benefit with marked nitroglycerin-induced hypotension. Circulation 1983;68:673-684.
16. Reimer KA, Jennings RB, Cobb FR, Murdock RH, Greenfield JC, et al: Animal models for protecting ischemic myocardium: Results of the NHLBI Cooperative Study. Circ Res 1985;56:651-665.
17. Bagchi D, Prasad R, Das KD: Direct scavenging of free radicals by captopril, an angiotensin converting enzyme inhibitor. Biochem Biophys Res Commun 1989;158:52-57.
18. Andreoli SP: Captopril scavenges hydrogen peroxide and reduces but does not eliminate oxidant-induced cell injury. Am J Physiol 1993;264: F120-F127.
19. Pi XJ, Chen X: Captopril and ramiprilat protect against free radical injury in isolated working hearts. J Mol Cell Cardioi 1989;21:1261-1271.
20. Chopra M, Beswick H, Clapperton M. Dargie HJ, Smith WE, McMurray J: Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: Free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 1992; 19:330-340.
21. Kilgore KS, Homeister JW, Satoh PS, Lucchesi BR: Sulfhydryl compounds, captopril and MPG inhibit complement-mediated myocardial injury. Am J Physiol 1994;266: H28-H35.
22. Hartman JC, Hullinger TG, Wall TM, Shebuski RJ: Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibitor. Eur J Pharmacol 1993;234:229-236.